EarlyCDT-Lung is being trialled by the NHS in the UK to establish its potential to select suitable patients for CT screening and diagnose lung cancer earlier

It is the world’s largest randomized clinical trial for the early detection of lung cancer using biomarkers in the blood

  • The trial is to establish if using EarlyCDT®Lung to identify those at high risk of lung cancer, followed by CT scanning, reduces the incidence of patients with late-stage lung cancer (III & IV) or unclassified presentation (U) at diagnosis, compared to standard practice in the UK
  • EarlyCDT-Lung positive High Level or Moderate Level test results are used to triage high-risk patients for serial CT scanning
  • The comparator (control arm) in the study is the current UK standard clinical practice of waiting for the development of symptoms of lung cancer and investigating symptoms according to national guidelines
  • The trial commenced in 2013, was fully recruited in July 2016 with 12,210 patients, and will report in 2019
  • Interim findings from the trial show that EarlyCDT-Lung has detected lung cancers at an earlier stage than in normal clinical practice. 75% of lung cancers in the study to date (n =16) were stage I & II. In standard UK clinical practice only 20% of lung cancers are diagnosed at this early stage, and 80% are diagnosed at stage III & IV


Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept